Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2024—Machaon Diagnostics has updated its genetic panel for detecting atypical hemolytic uremic syndrome. The aHUS genetic panel 3.0 now includes two more genes, for a total of 22, associated with thrombotic microangiopathies, including aHUS, thrombotic thrombocytopenic purpura, C3 glomerulopathy, congenital B12 deficiency, and others. Turnaround time is one week.
February 2024—FormaPath and the University at Buffalo Center for Advanced Technology in Big Data and Health Sciences (UB CAT) announced their collaboration to further test and develop FormaPath’s AdiPress, an automated lymph node dissection device.
February 2024—The Clinical and Laboratory Standards Institute has implemented new country-based pricing for countries that meet economic criteria set forth by the World Bank. Under this model, low- and lower-middle income countries receive a 90 percent discount off list prices and upper-middle income countries receive a 50 percent discount. The CLSI says that the pricing structure enables laboratories and clinicians around the world, regardless of resources, to more feasibly access its library of standards documents, training and support materials, and membership.
February 2024—Horiba Medical has launched the CE-IVDR–approved HELO 2.0 high-throughput automated hematology platform. The platform is composed of the Yumizen H1500 and H2500 high-throughput hematology analyzers, Yumizen T6000 automated conveyor, Yumizen P8000 middleware and expert validation station, and Yumizen SPS automatic slide maker. In addition, CellaVision digital cell morphology systems can be integrated with the P8000 middleware.
February 2024—Thermo Fisher Scientific announced an exclusive distribution agreement with Aesku Group to market, sell, and support Aesku’s portfolio of FDA-cleared immunofluorescence products, automated instruments, and software in the United States. The agreement expands Thermo Fisher’s immunology product portfolio of Elia autoimmune diagnostics, ImmunoCap allergy diagnostics, and Phadia systems to include complementary reagents and systems from Aesku.
Feburary 2024—BioMérieux has acquired the entire share capital of software company Lumed, increasing its stake from 16 to 100 percent. The acquisition of 84 percent of the capital represents an investment of about $9.75 million.
February 2024—Sekisui Diagnostics formalized an exclusive distribution agreement with Aptitude Medical Systems to sell the Aptitude Metrix COVID-19 test in the United States. The EUA-approved, single-use molecular in vitro diagnostic test is for the qualitative detection of nucleic acid from SARS-CoV-2 using anterior nasal swab and saliva samples.
February 2024—TechLab’s C. Diff Quik Chek Complete test is a rapid membrane enzyme immunoassay for the simultaneous detection of Clostridium difficile glutamate dehydrogenase antigen and toxins A and B in a single reaction well. Results are available in less than 30 minutes.
February 2024—Fujirebio announced the availability of its Lumipulse G pTau 217 plasma assay for the fully automated Lumipulse G immunoassay systems. The chemiluminescent enzyme immunoassay provides a quantitative measurement of pTau 217 in human K2EDTA plasma within 35 minutes. The assay is for research use only.
February 2024—Roche launched the LightCycler Pro system, designed and labeled for research and in vitro diagnostic workflows. Enhancements of this LightCycler system include a new vapor chamber for temperature uniformity across the block, new and improved software algorithms, and updated software and user interface. Users can develop their own tests or choose from a portfolio of more than 200 LightMix modular research assays and more than 60 LightMix CE-IVD assays from Roche subsidiary TIB Molbiol.
